Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia

Activating KIT D816V mutations are frequently found in CBF AML, which predicts for an unfavorable outcome. Dasatinib is a potent inhibitor of wildtype and mutant-KIT isoforms – including D816V. We now provide proof of antileukemic efficacy in a patient with relapsing mutant-KIT D816V CBF AML. Import...

Descripción completa

Detalles Bibliográficos
Autores principales: Kampa-Schittenhelm, Kerstin M., Vogel, Wichard, Bonzheim, Irina, Fend, Falko, Horger, Marius, Kanz, Lothar, Soekler, Martin, Schittenhelm, Marcus M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837740/
https://www.ncbi.nlm.nih.gov/pubmed/29545943
http://dx.doi.org/10.18632/oncotarget.24376
_version_ 1783304138845585408
author Kampa-Schittenhelm, Kerstin M.
Vogel, Wichard
Bonzheim, Irina
Fend, Falko
Horger, Marius
Kanz, Lothar
Soekler, Martin
Schittenhelm, Marcus M.
author_facet Kampa-Schittenhelm, Kerstin M.
Vogel, Wichard
Bonzheim, Irina
Fend, Falko
Horger, Marius
Kanz, Lothar
Soekler, Martin
Schittenhelm, Marcus M.
author_sort Kampa-Schittenhelm, Kerstin M.
collection PubMed
description Activating KIT D816V mutations are frequently found in CBF AML, which predicts for an unfavorable outcome. Dasatinib is a potent inhibitor of wildtype and mutant-KIT isoforms – including D816V. We now provide proof of antileukemic efficacy in a patient with relapsing mutant-KIT D816V CBF AML. Importantly, this effect is mediated via overriding the differentiation blockage of the leukemia clone. In addition, we show that dasatinib is capable to induce pulmonary differentiation syndrome – and therefore needs close monitoring of patients under therapy.
format Online
Article
Text
id pubmed-5837740
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-58377402018-03-15 Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia Kampa-Schittenhelm, Kerstin M. Vogel, Wichard Bonzheim, Irina Fend, Falko Horger, Marius Kanz, Lothar Soekler, Martin Schittenhelm, Marcus M. Oncotarget Case Report Activating KIT D816V mutations are frequently found in CBF AML, which predicts for an unfavorable outcome. Dasatinib is a potent inhibitor of wildtype and mutant-KIT isoforms – including D816V. We now provide proof of antileukemic efficacy in a patient with relapsing mutant-KIT D816V CBF AML. Importantly, this effect is mediated via overriding the differentiation blockage of the leukemia clone. In addition, we show that dasatinib is capable to induce pulmonary differentiation syndrome – and therefore needs close monitoring of patients under therapy. Impact Journals LLC 2018-01-31 /pmc/articles/PMC5837740/ /pubmed/29545943 http://dx.doi.org/10.18632/oncotarget.24376 Text en Copyright: © 2018 Kampa-Schittenhelm et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Case Report
Kampa-Schittenhelm, Kerstin M.
Vogel, Wichard
Bonzheim, Irina
Fend, Falko
Horger, Marius
Kanz, Lothar
Soekler, Martin
Schittenhelm, Marcus M.
Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
title Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
title_full Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
title_fullStr Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
title_full_unstemmed Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
title_short Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
title_sort dasatinib overrides the differentiation blockage in a patient with mutant-kit d816v positive cbfβ-myh11 leukemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837740/
https://www.ncbi.nlm.nih.gov/pubmed/29545943
http://dx.doi.org/10.18632/oncotarget.24376
work_keys_str_mv AT kampaschittenhelmkerstinm dasatiniboverridesthedifferentiationblockageinapatientwithmutantkitd816vpositivecbfbmyh11leukemia
AT vogelwichard dasatiniboverridesthedifferentiationblockageinapatientwithmutantkitd816vpositivecbfbmyh11leukemia
AT bonzheimirina dasatiniboverridesthedifferentiationblockageinapatientwithmutantkitd816vpositivecbfbmyh11leukemia
AT fendfalko dasatiniboverridesthedifferentiationblockageinapatientwithmutantkitd816vpositivecbfbmyh11leukemia
AT horgermarius dasatiniboverridesthedifferentiationblockageinapatientwithmutantkitd816vpositivecbfbmyh11leukemia
AT kanzlothar dasatiniboverridesthedifferentiationblockageinapatientwithmutantkitd816vpositivecbfbmyh11leukemia
AT soeklermartin dasatiniboverridesthedifferentiationblockageinapatientwithmutantkitd816vpositivecbfbmyh11leukemia
AT schittenhelmmarcusm dasatiniboverridesthedifferentiationblockageinapatientwithmutantkitd816vpositivecbfbmyh11leukemia

Ejemplares similares